Switching of Pyruvate Kinase Isoform L to M2 Promotes Metabolic Reprogramming in Hepatocarcinogenesis

Hepatocellular carcinoma (HCC) is an aggressive tumor, with a high mortality rate due to late symptom presentation and frequent tumor recurrences and metastasis. It is also a rapidly growing tumor supported by different metabolic mechanisms; nevertheless, the biological and molecular mechanisms invo...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 9; no. 12; p. e115036
Main Authors Wong, Carmen Chak-Lui, Au, Sandy Leung-Kuen, Tse, Aki Pui-Wah, Xu, Iris Ming-Jing, Lai, Robin Kit-Ho, Chiu, David Kung-Chun, Wei, Larry Lai, Fan, Dorothy Ngo-Yin, Tsang, Felice Ho-Ching, Lo, Regina Cheuk-Lam, Wong, Chun-Ming, Ng, Irene Oi-Lin
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 26.12.2014
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Hepatocellular carcinoma (HCC) is an aggressive tumor, with a high mortality rate due to late symptom presentation and frequent tumor recurrences and metastasis. It is also a rapidly growing tumor supported by different metabolic mechanisms; nevertheless, the biological and molecular mechanisms involved in the metabolic reprogramming in HCC are unclear. In this study, we found that pyruvate kinase M2 (PKM2) was frequently over-expressed in human HCCs and its over-expression was associated with aggressive clinicopathological features and poor prognosis of HCC patients. Furthermore, knockdown of PKM2 suppressed aerobic glycolysis and cell proliferation in HCC cell lines in vitro. Importantly, knockdown of PKM2 hampered HCC growth in both subcutaneous injection and orthotopic liver implantation models, and reduced lung metastasis in vivo. Of significance, PKM2 over-expression in human HCCs was associated with a down-regulation of a liver-specific microRNA, miR-122. We further showed that miR-122 interacted with the 3UTR of the PKM2 gene. Re-expression of miR-122 in HCC cell lines reduced PKM2 expression, decreased glucose uptake in vitro, and suppressed HCC tumor growth in vivo. Our clinical data and functional studies have revealed a novel biological mechanism involved in HCC metabolic reprogramming.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Competing Interests: Co-author Dr. Chun-Ming Wong is an editorial board member of PLOS ONE and this does not alter the authors’ adherence to PLOS ONE Editorial policies and criteria.
Conceived and designed the experiments: CCLW SLKA CMW IOLN. Performed the experiments: CCLW SLKA APWT IMJX RKHL DKCC LLW DNYF FHCT. Analyzed the data: CCLW SLKA RCLL CMW IOLN. Contributed reagents/materials/analysis tools: CCLW APWT IMJX RKHL LLW DNYF FHCT CMW IOLN. Wrote the paper: CCLW CMW IOLN. Obtained funding: CCLW IOLN. Study supervision: CCLW IOLN.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0115036